Bignell GR, Greenman CD, Davies H, et al. Signatures of mutation and selection in the cancer genome. Nature. 2010;463:893–8.
Ohta M, Inoue H, Cotticelli MG, et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell. 1996;84:587–97.
Pichiorri F, Palumbo T, Suh SS, et al. Fhit tumor suppressor: guardian of the preneoplastic genome. Future Oncol. 2008;4:815–24.
Waters CE, Saldivar JC, Hosseini SA, Huebner K. The FHIT gene product: tumor suppressor and genome “caretaker”. Cell Mol Life Sci. 2014;71:4577–87.
Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005;434:907–13.
Bartkova J, Horejsí Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434:864–70.
Sard L, Accornero P, Tornielli S, et al. The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci U S A. 1999;96:8489–92.
Joannes A, Grelet S, Duca L, et al. Fhit regulates EMT targets through an EGFR/Src/ERK/slug signaling axis in human bronchial cells. Mol Cancer Res. 2014;12:775–83.
Suh SS, Yoo JY, Cui R, et al. FHIT suppresses epithelial-mesenchymal transition (EMT) and metastasis in lung cancer through modulation of microRNAs. PLoS Genet. 2014;10:e1004652.
Ottey M, Han SY, Druck T, et al. Fhit-deficient normal and cancer cells are mitomycin C and UVC resistant. Br J Cancer. 2004;91:1669–77.
Okumura H, Ishii H, Pichiorri F, Croce CM, Mori M, Huebner K. Fragile gene product, Fhit, in oxidative and replicative stress responses. Cancer Sci. 2009;100:1145–50.
Barnes LD, Garrison PN, Siprashvili Z, et al. Fhit, a putative tumor suppressor in humans, is a dinucleoside 5′,5″’-P1, P3-triphosphate hydrolase. Biochemistry. 1996;35:11529–35.
Murphy GA, Halliday D, McLennan AG. The Fhit tumor suppressor protein regulates the intracellular concentration of diadenosine triphosphate but not diadenosine tetraphosphate. Cancer Res. 2000;60:2342–4.
Taverniti V, Seraphin B. Elimination of cap structures generated by mRNA decay involves the new scavenger mRNA decapping enzyme Aph1/FHIT together with DcpS. Nucleic Acids Res. 2014;43:482–92.
Li Y, Kiledjian M. Regulation of mRNA decapping. Wiley Interdiscip Rev RNA. 2010;1:253–65.
Draganescu A, Hodawadekar SC, Gee KR, Brenner C. Fhit-nucleotide specificity probed with novel fluorescent and fluorogenic substrates. J Biol Chem. 2000;275:4555–60.
Pelletier J, Graff J, Ruggero D, Sonenberg N. Targeting the eIF4F translation initiation complex: a critical nexus for cancer development. Cancer Res. 2015;75:250–63.
Sendoel A, Dunn JG, Rodriguez EH, et al. Translation from unconventional 5′ start sites drives tumour initiation. Nature. 2017;541:494–9.
Sozzi G, Pastorino U, Moiraghi L, et al. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res. 1998;58:5032–7.
Saldivar JC, Miuma S, Bene J, et al. Initiation of genome instability and preneoplastic processes through loss of Fhit expression. PLoS Genet. 2012;8:e1003077.
Kiss DL, Waters CE, Ouda IM, et al. Identification of Fhit as a post-transcriptional effector of thymidine kinase 1 expression. Biochim Biophys Acta. 2017;1860:374–82.
Druck T, Hadaczek P, TB F, et al. Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res. 1997;57:504–12.
Ingolia NT, Brar GA, Rouskin S, McGeachy AM, Weissman JS. The ribosome profiling strategy for monitoring translation in vivo by deep sequencing of ribosome-protected mRNA fragments. Nat Protoc. 2012;7:1534–50.
Zhong Y, Karaletsos T, Drewe P, et al. RiboDiff: detecting changes of mRNA translation efficiency from ribosome footprints. Bioinformatics. 2017;33:139–41.
Balakrishnan R, Oman K, Shoji S, Bundschuh R, Fredrick K. The conserved GTPase LepA contributes mainly to translation initiation in Escherichia Coli. Nucleic Acids Res. 2014;42:13370–83.
Song Y, Sun B, Hao L, et al. Elevated eukaryotic elongation factor 2 expression is involved in proliferation and invasion of lung squamous cell carcinoma. Oncotarget. 2016;7:58470–82.
Human protein atlas. https://www.proteinatlas.org. Accessed December 1, 2017.
Uhlén M, Björling E, Agaton C, et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics. 2005;4:1920–32.
Tillotson R, Selfridge J, Koerner MV, et al. Radically truncated MeCP2 rescues Rett syndrome-like neurological defects. Nature. 2017;550:398–401.
Oji Y, Tatsumi N, Fukuda M, et al. The translation elongation factor eEF2 is a novel tumor-associated antigen overexpressed in various types of cancers. Int J Oncol. 2014;44:1461–9.
Palam LR, Baird TD, Wek RC. Phosphorylation of eIF2 facilitates ribosomal bypass of an inhibitory upstream ORF to enhance CHOP translation. J Biol Chem. 2011;286:10939–49.
Barbosa C, Romão L. Translation of the human erythropoietin transcript is regulated by an upstream open reading frame in response to hypoxia. RNA. 2014;20:594–608.
Domaschenz R, Kurscheid S, Nekrasov M, Han S, Tremethick DJ. The Histone variant H2A.Z is a master regulator of the epithelial-Mesenchymal transition. Cell Rep. 2017;21:943–52.
Hinnebusch AG, Ivanov IP, Sonenberg N. Translational control by 5′-untranslated regions of eukaryotic mRNAs. Science. 2016;352:1413–6.
Kwon SC, Yi H, Eichelbaum K, et al. The RNA-binding protein repertoire of embryonic stem cells. Nat Struct Mol Biolf. 2013;20:1122–30.
Castello A, Fischer B, Eichelbaum K, et al. Insights into RNA biology from an atlas of mammalian mRNA-binding proteins. Cell. 2012;149:1393–406.
Castello A, Fischer B, Frese CK et al. Comprehensive identification of RNA-binding domains in human cells. Mol cell. 2016.
Siprashvili Z, Sozzi G, Barnes LD, et al. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci U S A. 1997;94:13771–6.
Pace HC, Garrison PN, Robinson AK, et al. Genetic, biochemical, and crystallographic characterization of Fhit-substrate complexes as the active signaling form of Fhit. Proc Natl Acad Sci U S A. 1998;95:5484–9.